Literature DB >> 30019352

WHO-5 and BDI-II are acceptable screening instruments for depression in people with diabetes.

N L Rauwerda1, K A Tovote2, A C T M Peeters3, R Sanderman2,4, P M G Emmelkamp5, M J Schroevers2, J Fleer2.   

Abstract

AIMS: To investigate the acceptability of two questionnaires, the five item WHO Well-being Index (WHO-5) and the Beck Depression Inventory II (BDI-II), which differ in length and focus, by comparing three screening groups: (1) WHO-5, (2) BDI-II and (3) WHO-5 and BDI-II.
METHODS: A total of 699 individuals with diabetes were approached to participate in the study, of whom 95 completed the WHO-5, 254 completed the BDI-II and 350 completed both the WHO-5 and the BDI-II questionnaires. Five facets of acceptability were compared, including objective aspects (response rate and completion level) and subjective aspects (appreciation, agreeableness and accuracy of the screening questionnaire). Data were analysed using logistic regression analysis and (multivariate) analysis of covariance.
RESULTS: The overall response rate was 65% (453 out of 699). No differences between the three groups were found with respect to the response rate (WHO-5: 66%; BDI-II: 63%; WHO-5 and BDI-II: 66%; P ≥ 0.19) and completion level (WHO-5: 99.5%; BDI-II: 97.8%; WHO-5 and BDI-II: 98.7%; P=0.45). The three groups did differ significantly in their scores on two of the three subjective indicators (P<0.03), i.e. appreciation (P=0.002) and agreeableness (P=0.035), with those completing only the WHO-5 reporting greater appreciation and agreeableness.
CONCLUSIONS: A brief well-being questionnaire, such as the WHO-5, results in greater appreciation of mood screening and appreciation of completing the questionnaire, but this does not result in a better response rate and higher questionnaire completion. Given these results, either or both questionnaires can be used to screen for depressive symptoms in people with diabetes in clinical practice.
© 2018 Diabetes UK.

Entities:  

Mesh:

Year:  2018        PMID: 30019352     DOI: 10.1111/dme.13779

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  3 in total

1.  Use of patient-reported outcome measures (PROMs) in clinical diabetes consultations: the DiaPROM randomised controlled pilot trial.

Authors:  Ingvild Hernar; Marit Graue; David A Richards; Ragnhild B Strandberg; Roy Miodini Nilsen; Magne Rekdal; Karianne Fjeld Løvaas; Tone V Madsen; Grethe S Tell; Anne Haugstvedt
Journal:  BMJ Open       Date:  2021-04-14       Impact factor: 2.692

2.  Development and Validation of the Depression Inventory for Type 1 Diabetes (DID-1).

Authors:  Mónica Carreira; María Soledad Ruiz de Adana; Marta Domínguez; Sergio Valdés; Maria Cruz Almaraz; Gabriel Olveira; María Teresa Anarte
Journal:  Int J Environ Res Public Health       Date:  2021-11-28       Impact factor: 3.390

3.  A Cross-Sectional Study to Examine the Psychological Impact of the COVID-19 Pandemic on Healthcare Workers in Kuwait.

Authors:  Sarah AlKandari; Ahmad Salman; Fatima Al-Ghadban; Rasheed Ahmad
Journal:  Int J Environ Res Public Health       Date:  2022-08-23       Impact factor: 4.614

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.